Cardiovascular clinical pharmacology of impedance reducing agents.
D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009566:Nitrates / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology; D005996:Nitroglycerin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009599:Nitroprusside / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D010646:Phentolamine / Q000494:pharmacology / Q000627:therapeutic use; D011224:Prazosin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
D009566:Nitrates; D014665:Vasodilator Agents; D009599:Nitroprusside; D006830:Hydralazine; D005996:Nitroglycerin; D011224:Prazosin; D010646:Phentolamine